+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Psoriatic Arthritis Therapeutics Market by Drug Class, by Disease Type Psoriatic Arthritis, Spondylitis, and Arthritis Mutilans, and by Distribution Channel: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 - 2025

  • ID: 4854190
  • Report
  • July 2019
  • Region: Global
  • 110 pages
  • Zion Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

The report covers a forecast and an analysis of the psoriatic arthritis therapeutics market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes the drivers and restraints of the psoriatic arthritis therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the psoriatic arthritis therapeutics market on a global level.

In order to give the users of this report a comprehensive view of the psoriatic arthritis therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the psoriatic arthritis therapeutics market by segmenting it based on drug class, disease type, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some major players of the global psoriatic arthritis therapeutics market include AbbVie, Amgen, Celgene Corporation, Janssen Biotech, UCB, Pfizer, Biogen, Novartis AG, Eli Lilly and Company, and Bristol-Myers Squibb.

This report segments the global psoriatic arthritis therapeutics market into:

Global Psoriatic Arthritis Therapeutics Market: Drug Class Analysis

  • Interleukin Inhibitors
  • TNF Inhibitors
  • PDE4 Inhibitors
  • Others

Global Psoriatic Arthritis Therapeutics Market: Disease Type Analysis

  • Asymmetric Psoriatic Arthritis
  • Symmetric Psoriatic Arthritis
  • Distal Interphalangeal Predominant (DIP) Psoriatic Arthritis
  • Spondylitis
  • Arthritis Mutilans

Global Psoriatic Arthritis Therapeutics Market: Distribution Channel Analysis

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Global Psoriatic Arthritis Therapeutics Market: Regional Analysis

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global psoriatic arthritis therapeutics market, 2016-2025 (USD Billion)
    • 2.2. Global psoriatic arthritis therapeutics market: Snapshot
  • Chapter 3. Infection Control Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global psoriatic arthritis therapeutics market drivers: impact analysis
      • 3.2.2. Increasing prevalence of psoriatic arthritis therapeutics
      • 3.2.3. The rising use of biologics
    • 3.3. Market Restraints
      • 3.3.1. Global psoriatic arthritis therapeutics market restraints: impact analysis
      • 3.3.2. The high cost of drugs
      • 3.3.3. The stringent regulatory approval process
    • 3.4. Opportunities
      • 3.4.1. Flourishing medical device and pharmaceutical industries in emerging economies
      • 3.4.2. Increasing investments by major market players
      • 3.4.3. Growing R&D activities
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by drug class
      • 3.6.2. Market attractiveness analysis, by disease type
      • 3.6.3. Market attractiveness analysis, by distribution channel
      • 3.6.4. Market attractiveness analysis, by region
  • Chapter 4. Global Infection Control Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global psoriatic arthritis therapeutics market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Infection Control Market - Drug Class Analysis
    • 5.1. Global psoriatic arthritis therapeutics market: drug class overview
      • 5.1.1. Global psoriatic arthritis therapeutics market revenue share, by drug class, 2018 and 2025
    • 5.2. Interleukin Inhibitors
      • 5.2.1. Global psoriatic arthritis therapeutics market for Interleukin Inhibitors, 2016-2025 (USD Billion)
    • 5.3. TNF Inhibitors
      • 5.3.1. Global psoriatic arthritis therapeutics market for TNF Inhibitors, 2016-2025 (USD Billion)
    • 5.4. PDE4 Inhibitors
      • 5.4.1. Global psoriatic arthritis therapeutics market for PDE4 Inhibitors, 2016-2025 (USD Billion)
    • 5.5. Others
      • 5.5.1. Global psoriatic arthritis therapeutics market for others, 2016-2025 (USD Billion)
  • Chapter 6. Global Infection Control Market - Disease Type Analysis
    • 6.1. Global psoriatic arthritis therapeutics market: disease type overview
      • 6.1.1. Global psoriatic arthritis therapeutics market revenue share, by disease type, 2018 and 2025
    • 6.2. Asymmetric Psoriatic Arthritis
      • 6.2.1. Global psoriatic arthritis therapeutics market for Asymmetric Psoriatic Arthritis, 2016-2025 (USD Billion)
    • 6.3. Symmetric Psoriatic Arthritis
      • 6.3.1. Global psoriatic arthritis therapeutics market for Symmetric Psoriatic Arthritis, 2016-2025 (USD Billion)
    • 6.4. Distal Interphalangeal Predominant (DIP) Psoriatic Arthritis
      • 6.4.1. Global psoriatic arthritis therapeutics market for Distal Interphalangeal Predominant (DIP) Psoriatic Arthritis, 2016-2025 (USD Billion)
    • 6.5. Spondylitis
      • 6.5.1. Global psoriatic arthritis therapeutics market for Spondylitis, 2016-2025 (USD Billion)
    • 6.6. Arthritis Mutilans
      • 6.6.1. Global psoriatic arthritis therapeutics market for Arthritis Mutilans, 2016-2025 (USD Billion)
  • Chapter 7. Global Infection Control Market - Distribution Channel Analysis
    • 7.1. Global psoriatic arthritis therapeutics market: distribution channel overview
      • 7.1.1. Global psoriatic arthritis therapeutics market revenue share, by distribution channel, 2018 and 2025
    • 7.2. Hospital Pharmacies
      • 7.2.1. Global psoriatic arthritis therapeutics market for Hospital Pharmacies, 2016-2025 (USD Billion)
    • 7.3. Online Pharmacies
      • 7.3.1. Global psoriatic arthritis therapeutics market for Online Pharmacies, 2016-2025 (USD Billion)
    • 7.4. Retail Pharmacies
      • 7.4.1. Global psoriatic arthritis therapeutics market for Retail Pharmacies, 2016-2025 (USD Billion)
  • Chapter 8. Global Infection Control Market - Regional Analysis
    • 8.1. Global psoriatic arthritis therapeutics market: regional overview
      • 8.1.1. Global psoriatic arthritis therapeutics market revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.2.2. North America psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
      • 8.2.3. North America psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.2.4.2. The U.S. psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.2.4.3. The U.S. psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.2.5.2. Rest of North America psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.2.5.3. Rest of North America psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.3.2. Europe psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
      • 8.3.3. Europe psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.4. UK
        • 8.3.4.1. UK psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.4.2. UK psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.3.4.3. UK psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.5. Germany
        • 8.3.5.1. Germany psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.5.2. Germany psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.3.5.3. Germany psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.6.2. France psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.3.6.3. France psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.7.2. Rest of Europe psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.3.7.3. Rest of Europe psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.4.2. Asia Pacific psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
      • 8.4.3. Asia Pacific psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.4. China
        • 8.4.4.1. China psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.4.2. China psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.4.4.3. China psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.5. Japan
        • 8.4.5.1. Japan psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.5.2. Japan psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.4.5.3. Japan psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.6. India
        • 8.4.6.1. India psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.6.2. India psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.4.6.3. India psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.7.2. Rest of Asia Pacific psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.4.7.3. Rest of Asia Pacific psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.5.2. Latin America psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
      • 8.5.3. Latin America psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.5.4.2. Brazil psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.5.4.3. Brazil psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.5.5.2. Rest of Latin America psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
        • 8.5.5.3. Rest of Latin America psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa psoriatic arthritis therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.6.2. The Middle East and Africa psoriatic arthritis therapeutics market revenue, by disease type, 2016-2025 (USD Billion)
      • 8.6.3. The Middle East and Africa psoriatic arthritis therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
  • Chapter 9. Company Profile
    • 9.1. AbbVie
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Amgen
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Janssen Biotech, Inc.
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. UCB
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Celgene Corporation
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Pfizer
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Biogen
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Novartis AG
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Eli Lilly and Company
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Bristol-Myers Squibb
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll